European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV*
Open Access
- 31 January 2008
- journal article
- practice guideline
- Published by Wiley in HIV Medicine
- Vol. 9 (2) , 72-81
- https://doi.org/10.1111/j.1468-1293.2007.00534.x
Abstract
Background Metabolic diseases are frequently observed in HIV‐infected persons and, as the risk of contracting these diseases is age‐related, their prevalence will increase in the future as a consequence of the benefits of antiretroviral therapy (ART). Summary of guidelines All HIV‐infected persons should be screened at regular intervals for a history of metabolic disease, dyslipidaemia, diabetes mellitus, hypertension and alteration of body composition; cardiovascular risk and renal function should also be assessed. Efforts to prevent cardiovascular disease will vary in intensity depending on an individual's absolute risk of ischaemic heart disease and should be comprehensive in nature. Lifestyle interventions should focus on counselling to stop smoking, modify diet and take regular exercise. A healthy diet, exercise and maintaining normal body weight tend to reduce dyslipidaemia; if not effective, a change of ART should be considered, followed by use of lipid‐lowering medication in high‐risk patients. A pre‐emptive switch from thymidine analogues is recommended to reduce the risk of development or progression of lipoatrophy. Intra‐abdominal fat accumulation is best managed by exercise and diet. Prevention and management of type 2 diabetes mellitus and hypertension follow guidelines used in the general population. When using medical interventions to prevent and/or treat metabolic disease(s), impairment of the efficacy of ART should be avoided by considering the possibility of pharmacokinetic interactions and compromised adherence. Specialists in HIV and specialists in metabolic diseases should consult each other, in particular in difficult‐to‐treat cases. Conclusion Multiple and relatively simple approaches exist to prevent metabolic diseases in HIV‐infected persons; priority should be given to patients at high risk of contracting these diseases.Keywords
This publication has 15 references indexed in Scilit:
- Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus DiseaseJournal of Clinical Endocrinology & Metabolism, 2007
- Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: replyEuropean Heart Journal, 2007
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2007
- Current Concepts in the Diagnosis and Management of Metabolic Complications of HIV Infection and Its TherapyClinical Infectious Diseases, 2006
- The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D:A:D StudyHIV Medicine, 2006
- Practice Guidelines For Primary Care PhysiciansJournal Of Hypertension, 2003
- Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials GroupClinical Infectious Diseases, 2003
- A cure for cardiovascular disease?BMJ, 2003
- Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapyAIDS, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001